Delta Electronics agreed to acquire cancer diagnostics company ACT Genomics from Prenetics Global for up to $71.78 million (NT$2.15 billion), marking the Taiwanese manufacturer’s boldest push yet into healthcare beyond its traditional power management business.
The transaction gives Delta access to ACT Genomics’ next-generation sequencing technology for cancer detection, though the industrial giant will be entering a crowded precision medicine market dominated by established players. ACT Genomics operates across Taiwan, Singapore, Japan, Thailand and Hong Kong, providing Delta with an immediate regional footprint.
The acquisition represents a significant strategic shift for Delta, which has primarily focused on power supplies and industrial automation. While Delta already provides medical-grade power supplies to healthcare equipment manufacturers, cancer diagnostics requires different expertise and regulatory navigation.
Prenetics will receive approximately $46 million in proceeds, using the cash to focus on its consumer health brands after struggling with business complexity that investors had criticized. The deal requires Delta to obtain at least 90% of ACT Genomics’ shares and regulatory approvals.
ACT Genomics, founded in 2014, gained credibility as the first non-U.S. company to receive FDA authorization for comprehensive cancer genetic testing. However, Delta will face intense competition from better-funded diagnostics giants already established in precision oncology.
Word count: 219 words
